CSPC PHARMA's new drug SYH2066 has been approved to conduct clinical trials
CSPC PHARMA (01093.HK) announced that its main research and development chemical class 1 new drug SYH2066 tablets have been approved by the National Medical Products Administration of China to conduct clinical trials in China. The approved indication is for the treatment of respiratory infections caused by respiratory syncytial virus
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments